Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics is expected to see continued success with its flagship product, Korlym, which is seeing strong demand and now has an authorized generic version available. Additionally, the company has a diverse pipeline of promising treatments in various stages of clinical trials, which provide potential for future growth. The recent approval and launch of Lifyorli in platinum-resistant ovarian cancer are also positive indicators for the company's financial outlook. While risks such as commercial, clinical, and regulatory challenges remain, the company's recent financial performance and positive developments suggest a strong potential for continued success and growth in the future.

Bears say

Corcept Therapeutics is facing a negative outlook due to their reliance on one main drug, Korlym, for revenue and their limited pipeline. With limited data on their other compounds, the market may not have confidence in their potential to diversify and continue revenue growth. Furthermore, the company's financials show a decrease in revenue and net income in the 2020 fiscal year compared to the previous year, further exacerbating concerns about their future success.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.